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Abstract
Purpose To evaluate the contribution of germline
BRCA1 mutations in the incidence of hereditary and
familial Breast Cancer (BC) and/or Ovarian Cancer
(OC) in patients from Southern Italy (in the region of
Sicily) and to identify a possible association between
the higher frequency of BRCA1 mutations and a spe-
cific familial profile.
Experimental design A consecutive series of 650 pa-
tients with BC and/or OC diagnosed between 1999 and
2005 were recruited from the Southern Italian region
of Sicily, after interview at the ‘‘Regional Reference
Centre for the Characterization and Genetic Screening
of Hereditary Tumors’’ at the University of Palermo.
Genetic counselling allowed us to recruit a total of 106
unrelated families affected with breast and/or ovarian
cancer screened for mutations occurring in the whole
BRCA1 gene by automatic direct sequencing.
Results Germline BRCA1 mutations were found in
17 of 106 (16%) Sicilian families. The HBOC profile
had a major frequency (66%) of mutations (P < 0.01).
A total of 28 sequence variants was identified. Seven of
these were pathogenic, 5 unknown biological variant
(UV) and 16 polymorphisms. We also identified a
pathological mutation (4843delC) as a possible Sicilian
founder mutation.
Conclusions The present study is the first BRCA1
disease-associated mutations analysis in Southern
Italian families. The early age of onset of such tumors
and the association with the HBOC familial profile
could be two valid screening factors for the identifica-
tion of BRCA1 mutation carriers. Finally, we identified
a BRCA1 mutation with a possible founder effect.
Keywords BRCA1  Genetic testing  Breast cancer 
Ovarian cancer
Introduction
From 15 to 20% of breast and/or ovarian cancers
(BC and/or OC) occur in patients with a strong
familial history and are associated with a polygenic
susceptibility of low-risk alleles, while 5–10% are
hereditary tumors and are associated with mutations
in specific genes, mainly in the Breast Cancer 1 gene
(BRCA1) [1–3]. This gene codifies for a nuclear
phosphoprotein that negatively regulates the cell cy-
cle and is actively involved in the maintenance of
genome stability [4].
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The detection of BRCA1 gene alterations has be-
come the molecular basis of genetic testing, which
makes it possible to recognize subjects who are carriers
of the germline mutation in this gene and at ‘‘high
risk’’ of developing BC and/or OC [5, 6]. Women
carriers of BRCA1 mutations may develop a BC in 56–
80% and an OC in 10–30% of cases up to 70 years old.
In addition, women affected by BC and carriers of a
known BRCA1 mutation show a 40–60% risk of
developing a second breast tumor, while males with
BRCA1 mutations show a risk of less than 1% of
developing BC [7–10]. BRCA1 mutations also appear
to be associated with a higher risk of developing
prostatic, colorectal and pancreatic tumors [11]. In the
Italian population particularly, BRCA1 mutation car-
riers have a probability of about 40% of developing BC
and/or OC up to the age of 70 [12, 13]. Unfortunately,
these data do not include information regarding the
Sicilian population and no data involving BRCA1
mutational screening in this specific population are yet
available.
Although BRCA1 mutations span the whole gene,
without any hot spot loci, a major incidence of specific
BRCA1 gene mutations has been identified according
to the ethnic group and geographical area [14]. The
identification of some of these mutations with a foun-
der effect has been reported in several countries,
including Italy and this may have an important prac-
tical implication for genetic testing [15–18].
More than 600 pathogenic mutations in the BRCA1
gene have been identified in families presenting BC
and/or OC and reported in the BIC (Breast cancer
Information Core) database [19]. Of these, about 90%
give rise to a functionally inactive truncated protein. In
addition, many studies have recently reported that
some genetic variants of unclassified clinical signifi-
cance, the so-called unknown biological variant (UV),
may play a specific role in the detection of the risk of
developing BC and/or OC [20]. The discrimination of
deleterious/high-risk variant from the neutral/low-risk
one is a very important key-point for the assessment of
a specific clinical significance of a variant and, conse-
quently, conclusive results of genetic counseling. For
this reason, many different methods have been widely
used in a large number of laboratories including the
cosegregation analysis, the measure of the influence of
the UVs on the protein activity and the comparison of
sequence conservation across species [21, 22].
The aim of this study is, first at all, to determine the
contribution of germline BRCA1 mutations in the
incidence of hereditary and familial BC and/or OC in
patients from the Southern Italian region of Sicily.
Furthermore, we hoped to identify a possible associa-
tion between the higher frequency of BRCA1 muta-
tions and a specific familial profile.
Patients and methods
Recruitment criteria and study plan
A consecutive series of 650 patients from the Southern
Italian region of Sicily, with BC and/or OC diagnosed
between 1999 and 2005, were recruited after interview
at the ‘‘Regional Reference Centre for the Charac-
terization and Genetic Screening of Hereditary Tu-
mors’’ at the University of Palermo. Written informed
consent was obtained from all patients, who then
underwent genetic counseling. The patients received
information regarding the aims and limits of genetic
testing. Genetic counseling was conducted by an
oncologist, a geneticist and a psychologist and included
information regarding the personal and familial history
of patients (Table 1), in order to make it possible for us
to evaluate risk assessment and the genealogic tree.
The latter was updated every year and investigated for
at least three generations in those patients with breast/
ovarian cancer or other types of tumors, in order to
evaluate the presence within the family of other types
of neoplasias related to BRCA1 alteration. All infor-
mation regarding the proband and the affected rela-
tives was verified and confirmed by means of analysis
of their hospital records. All cancer diagnosis was
confirmed by pathology reports.
After consideration of the various family relation-
ships, a total of 106 unrelated families affected with
breast and/or ovarian cancer proved to be eligible for
inclusion in an ongoing study (Table 1) [23, 24] and
were screened for mutations occurring in the whole
BRCA1 gene by automatic direct sequencing. None of
families met the strict criteria for other known syn-
dromes involving breast cancer, such as ataxia-te-
langectasia, Cowden disease or Li-Fraumeni syndrome.
All the material regarding each individual case (a per-
sonal data chart, interviews, blood samples) was filed
under an individual personal code respecting the pa-
tient’s privacy. For each family, we selected the youn-
gest member with breast and/or ovarian cancer as the
index case for BRCA1 mutation screening. When a
BRCA1 mutation had been identified, the sequencing
procedure was repeated a second time in order to
confirm the result. In cases of positive testing, the pa-
tients were invited to follow preventative programs for
the early diagnosis of BRCA1-associated tumors and to
communicate the results to their first-degree relatives
so that they might undergo genetic counseling. When
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this proved negative, the relatives of such patients were
encouraged to take a regular part in the early diagnosis
programs for their familial condition of cancer risk. If
the result of genetic testing was unclear, the patient was
informed of this fact in order to decide whether or not
to proceed to other biomolecular investigations.
Patient and control population features
The group studied was made up of 7% males (7/106)
and 93% females (99/106). Eighty-seven percent (92/
106) of the patients were affected by breast cancer,
22% (20/92) of these with bilateral BC. Furthermore,
8% (9/106) involved women with OC while 5% (5/106)
were women affected by both diseases.
Seventy-one percent (75/106) of the patients were
included in the population study only because of their
personal history of tumors, 15% (16/106) both because
of personal and family history of first degree tumors
and only 14% (15/106) were studied for family history
of first degree tumors (Table 1). Sixty-two percent (56/
91) of the patients with a personal tumor history had
developed both breast and/or ovarian cancers at an
early age (£40 years).
Frequencies of previously unreported BRCA1
variants were also established on a control population
composed of 50 healthy Sicilian donors over fifty
without familial history for these tumors.
Mutational screening of the gene BRCA1
All the samples were analyzed anonymously. Genomic
DNA was extracted from the whole peripheral blood
of each proband according to the instructions con-
tained in the QIAamp Blood Kit (Qiagen, Hilden,
Germany). A 9700 thermal cycler (Applied Biosys-
tems, Foster City, CA) was used to perform the poly-
merase chain reaction (PCR) of all the exons, the
exon–intron boundaries and of the 12 overlapping
fragments constituting exon 11 of the gene BRCA1 [25,
26]. The amplicons were checked by means of agarose
gel electrophoresis at a concentration ranging from 1.5
to 2% and were stained with ethidium bromide. Direct
sequencing of the PCR products was performed using a
BigDye Terminator v3.1 Cycle sequencing Kit and an
ABI PRISM 3100 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA). Each genetic variant was
confirmed by direct sequencing analysis on two inde-
pendent blood samples.
Mutation nomenclature and interpretation
of sequence analysis results
All genetic variants were named according to the
convention of BIC database [19] and the systematic
nomenclature [27]. Sequence variants detected by
molecular analysis were classified as deleterious
mutations, polymorphisms and variants of unknown
significance.
Mutations were considered deleterious, if they pre-
maturely truncated the proteic product at least 10
amino acids before C-terminus. In addition, specific
missense mutations and noncoding sequence mutations
were interpreted as deleterious/high risk on the basis of
data derived from the linkage analysis of high risk
families, functional assays, biochemical analysis or
demonstration of abnormal mRNA transcript pro-
cessing. When there was clear evidence of presumed
deleterious mutation, the mutations were reported as
suspected deleterious, and were included in the posi-
tive group. Missense mutations and mutations occur-
ring in analyzed intronic regions have not yet been
determined as variants of unknown significance. Those
variants which do not modify exon splicing, do not
change amino acids or change them without any sub-
stantial clinical consequence and which have been
identified with a frequency major or equal to 2% were
considered as polymorphisms.
Immunohistochemistry
Immunohistochemical analyses were performed on
serial sections of 2 lm as previously reported [28]. The
slides were immunostained with the following primary
monoclonal antibodies: anti-ER (clone 1D5, dilution
1:35, Dako Cytomation, Denmark), anti-PR (clone
Table 1 Study recruitment criteria and distribution of families
according to index cases among the overall series of 106 families
enrolled in the study
Characteristics Number Frequency (%)
Personal history 75
BC £ 40 years 43 57
OC £ 40 yrs 6 8
BC and OC (any age) 3 4
Bilateral BC 13 17
BC £ 40 yrs and bilateral 1 1
Male BC 7 9
Multiple tumors in the same pts
(one of which BC or OC)
2 3
First degree family history 31
Two BC cases (one £ 40 years) 12 39
Two OC cases (one £ 40 years) 3 10
Two carcinomas cases
(one BC and/or OC at any age)
5 16
Three or more BC cases 9 29
Multiple tumors in the same family
(one of which BC or OC)
2 6
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PgR 636, dilution 1:50, Dako Cytomation, Denmark)
and anti c-erB-2 (Polyclonal, dilution 1:250, Dako
Cytomation, Denmark). Negative controls were car-
ried out using non-immune sera instead of the primary
antibody. For each of the markers studied, the positive
tumor cells were quantified by two independent
observers by evaluating at least 2000 cells from four
different specimens of the same tumors and were ex-
pressed as percentage ratio of total number of tumor
cells. Inter-observer variation was less than 5%; dif-
ferences were discussed and a consensus was reached.
Slides used for ER and PgR were scored as positive
when at least 10% of the tumor cells showed nuclear
staining c-erB-2 positive score were defined when the
percentages of immunopositive cancer cells (any la-
beled cancer cell membrane) were >25%. All samples
were evaluated blind without any knowledge of either
clinical diagnosis or histological parameters.
Statistical analysis
The statistical association between mutation frequency
and the other parameters was assessed using a v2-test.
Differences were considered to be significant when the
P-value was less than 0.05. Statistical analyses were
carried out with the SPSS statistical software (SPSS
Inc., Chicago, IL).
Results
BRCA1 mutational screening
Germline BRCA1 mutations were found in 17 of 106
(16%) Sicilian families. Families were grouped
according to four profiles: Hereditary Breast Cancer
(HBC, with ‡ 2 cases of female breast cancer);
Hereditary Ovarian Cancer (HOC, with cases of
ovarian cancer); Hereditary Breast and Ovarian Can-
cer (HBOC, with cases of breast and ovarian cancer);
Male Breast Cancer (MBC, with at least one case of
male breast cancer). According to the analysis of the
different familial profiles, and also taking into consid-
eration the II degree, the HBOC profile had a major
frequency (66%) of mutations (P < 0.01) (Table 2).
No instances of HBOC families with male breast
cancer cases were observed. A total of 28 sequence
variants was identified (Table 3). Sixty-four percent
(18/28) were missense mutations, 18% (5/28) were
frameshift mutations, 7% (2/28) were nonsense muta-
tions and 11% (3/28) were intronic variants. Five of
eighteen (28%) missense mutations were unknown
biological variants (UV). According to the mutation
effects, 7 were pathogenic, 5 suspected deleterious UV
and 16 polymorphisms. All the pathogenic and un-
known variants in the BRCA1 gene were distributed
throughout the whole gene.
Pathogenic mutation
Pathogenic mutations were detected in twelve families
(11%) of our cohort. Six of these were HBOC, four
were HBC, one HOC and one MBC (Table 4). All the
families with carriers of a deleterious mutation had at
least one member with early onset of BC and/or OC.
Seven different pathogenic mutations leading to
non-functional truncated proteins were identified
(Y101X, 633delC, 916delTT, R1443X, 4843delC,
5083del19 and 5149del4).
The Y101X mutation, detected once in the BIC
database, was identified in two cases affected by OC
(index case, 37 years) and BC (33 years) respectively,
with HBOC profile (FAM49).
The 633delC mutation was identified in an HOC
profile (FAM76) containing 3 cases of OC at ages 40
(grandmother), 45 (index case) and 29 (daughter). The
other daughter was a healthy carrier of the same
mutation.
Table 2 Associations between familial profile and pathological
variables of 106 index cases and BRCA1 mutational status
BRCA1
wt (%)
BRCA1
mutation (%)
P
Familial profile (n)
HBC (83) 75 (90) 8 (10) <0.01
HOC (6) 5 (83) 1 (17)
MBC (7) 5 (71) 2 (29)
HBOC (10) 4 (40) 6 (60)
Breast cancer histotype (n)
CDI (77) 66 (86) 11 (14) NS
CLI (9) 8 (89) 1 (11)
CM (1) 1 (100) 0 (0)
CDI and CLI (9) 8 (89) 1 (11)
Breast cancer grading (n)
G1 (16) 15 (94) 1 (6) NS
G2 (32) 30 (94) 2 (6)
G3 (29) 19 (65) 10 (35)
Ovarian cancer histotype (n)
(6) 5 (83) 1 (17) NS
(4) 2 (50) 2 (50)
(1) 1 (100) 0 (0)
Ovarian cancer grading (n)
G1 (0) 0 0 NS
G2(4) 2 (50) 2 (50)
G3 (3) 2 (67) 1 (33)
HBC (Hereditary breast cancer), HBOC (Hereditary breast and/
or ovarian cancer), HOC (Hereditary ovarian cancer), MBC
(Male breast cancer)
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Table 3 BRCA1 sequence variants identified in 106 unrelated families: M, missense mutation; F, frameshift mutation; N, nonsense
mutation; IVS intronic variant sequence; UV, unknown variant; P, polymorphism
Sequence variant
designation
Systematic
nomenclature
Exon NT Codon Base
change
AA
Change
Mutation
type
Mutation
effect
N pts Times
in BIC
I68K c.223T>A 5 322 68 T to A Ile/Lys M UV 1 1
Y101X c.303T>G 7 422 101 T to G Tyr/Stop N N 1 1
IVS 7-34 C/T c.81-34C>T 7 –34 – C to T – IVS P 17 7
IVS 8-58 delT c.548-58delT 8 663-58 – DelT – IVS P 10 7
Y179C c.536A>G 8 655 179 A to G Tyr/Cys M UV 1 16
633delC c.514delC 8 633 172 DelC Stop233 F F 2 16
916delTT c.797_798delTT 11 916 266 DelTT Stop285 F F 2 2
Q356R c.1067A>G 11 1186 356 A to G Gly/Arg M P 7 21
F486L c.1456T>C 11 1575 486 T to C Feu/Leu M P 1 17
A521T c.1561G>A 11 1680 521 G to A Ala/Thr M UV 2 2
N550H c.1648A>C 11 1767 550 A to C Asn/His M UV 1 34
D693N c.2077G>A 11 2196 693 G to A Asp/Asn M P 8 16
2201C/T c.2082C>T 11 2201 694 C to T Ser/Ser M P 38 11
V740L c.2218G>C 11 2337 740 G to C Val/Leu M UV 1 1
2430T/C c.2311T>C 11 2430 771 T to C Leu/Leu M P 23 25
P871L c.2612C>T 11 2731 871 C to T Pro/Leu M P 54 24
E1038G c.3113A>G 11 3232 1038 A to G Glu/Gly M P 66 32
S1040N c.3119G>A 11 3238 1040 G to A Ser/Asn M P 4 23
K1183R c.3548A>G 11 3667 1183 A to G Lys/Arg M P 52 31
R1443X c.4327C>T 13 4446 1443 C to T Arg/Stop N N 1 100
4427T/C c.4308T>C 13 4427 1436 T to C Ser/Ser M P 47 15
S1512I c.4535G>T 15 4654 1512 G to T Ser/Ile M P 1 52
5083del19 c.4964_4982del19 16 5083 1655 del 19bp Stop1670 F F 4 38
4843delC c.4724delC 16 4843 1575 DelC Stop1600 F F 2 0
S1613G c.4837A>G 16 4956 1613 A to G Ser/Gly M P 57 34
M1652I c.4956G>A 16 5075 1652 G to A Met/Ile M P 6 38
5149del4 c.5030_5033del4 17 5149 1677 delCTAA Stop1678 F F 2 16
IVS 18 + 66G/A c.5093 + 66G>A 18 5272 – G to A – IVS P 30 8
Table 4 BRCA1 alteration identified. In withe rows the index cases (12/106) with deleterious mutations, in gray the index cases (5/106)
with BRCA1 missense mutations with unknown biological significance
Mutations in
BRCA 1 gene
Family ID Familial
profile
Index case
status (age)
Family History
(BC/OC; age)
Hystotipe/
Grades
ER PgR c-ErB-2
R1443X FAM 22 MBC BCm (60) 2BC (36, 60) IDC G2 – – –
5149del4 FAM 7 HBC BC 50 3BC (35, 50, 51) IDC e LC G3 – – +
5083del19 FAM 71 HBC BC bil (40) IDC G3 – – –
916delTT FAM 43 HBC BC bil (33) IDC G3 – – –
5083del19 FAM 102 HBC BC (39) IDC G3 – + +
633delC FAM 76 HOC OC (45) 3OC (29, 40, 45) CAp/m G3
916delTT FAM 46 HBOC BC (32) BC/OC (32/ 63) IDC G3 – – +
4843delC FAM 64 HBOC BC (44) 2BC (40, 44) IDC G2 – – +
5083del19 FAM 78 HBOC BC bil (75) BC/OC (75/39) IDC G3 + + –
5083del19 FAM 106 HBOC BC bil (42) 3OC (32, 42, 50) IDC G3 – – +
4843delC FAM 92 HBOC OC (46) BC/2OC (52/40, 42) Cap G3
Y101X FAM 49 HBOC OC (37) CAp/m G2
I68K FAM 3 HBC BC (32) IDC G3 – – +
A521T FAM 19 MBC BCm (47) IDC G2 + + +
A521T FAM 20 HBC BC (39) IDC G3 – – +
Y179C & N550H FAM 79 HBC BC (35) LC G2 + + –
V740L FAM 90 HBC BC (33) IDC G2 + + –
N, nonsense; F, frameshift; M, missense. IDC (invasive ductal carcinoma), LC (lobular carcinoma). HBC (Hereditary breast cancer),
HBOC (Hereditary breast and/or ovarian cancer), HOC (Hereditary ovarian cancer), MBC (Male breast cancer). CAp: Cystoade-
carcinoma papillary; CAp/m: Cystoadecarcinoma mucinous and papillary; AE: Adenocarcinoma Endometroid; CCA: Clear Cell
(mesonephroid) Adenocarcinoma
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Two specific French mutations (R1443X and
916delTT) were found in 3 different families (FAM22,
FAM43 and FAM46). The first one is the most com-
mon alteration reported in the BIC database while it is
important to emphasize that the other one is reported
only twice. In particular, the FAM43 family presented
two bilateral breast cancer cases at ages of 33 (index
case) and 40 as well as four other types of cancer (2
prostate, 1 pancreas and 1 gastric). The R1443X
mutation was identified in a family with MBC profile
(FAM22) which included a male breast cancer (index
case) and a female breast cancer at ages 60 and 36
respectively.
The 5149del4 mutation was identified in a family
(FAM7) with an HBC profile containing 3 sisters with
BC at ages 35, 50 (index case), and 51.
The 4843delC mutation had not been reported ei-
ther in the BIC or in the Human Gene Mutation Da-
tabases (http://www.archive.uwwcm.ac.uk/uwcm/mg)
and is therefore considered novel. This pathogenic
mutation was found in two unrelated families (FAM 64
and FAM 92) from the same restricted geographical
area of the south-western area of Palermo, in the
Italian Region of Sicily. This mutation is located in
exon 16 and generates a stop codon at position 1600 of
BRCA1 gene. The sequencing analysis showed that
both mutation carriers had the same sequence variants
(P871L, E1038G, K1183R, 4427T/C, S1613G, M1652I,
IVS 18 + 66 G>A). Furthermore, both the carriers
showed a strong family history. The sequencing anal-
ysis conducted, in fact, on the healthy carriers of the
families showed that the I and II degree relatives af-
fected by BC or OC had the same mutations (Fig. 1).
The frameshift mutation 5083del19 proved to be the
mutation with the higher incidence (4/12) and three of
the four carriers had a bilateral breast cancer.
Unknown biological variants
Five unknown biological variants (I68K, Y179C,
A521T, N550H, V740L) were identified in five families
(Table 3). All UV mutations carriers showed only a
personal history of early-onset tumors or of male BC
(Table 4).
None of the UV mutations were found in any of the
50 control populations.
The I68K mutation gives rise to the substitution of
isoleucyne 68, characterized by the presence of a bur-
ied hydrophobic group, by lysine, which is a basic
amino acid. This substitution modifies the BRCA1
interaction with the E2 ubiquitin ligase enzyme and it
may have a pathogenic effect.
The genetic testing of the FAM79 index case iden-
tified in the gene BRCA1 sequence two missense
mutations in cis, Y179C and N550H. Furthermore,
these alterations were associated with the rare substi-
tution of F486L, of low clinical significance or neutral
(LCS/neutral).
The V740L and A521T mutations are rare unknown
variants reported in the BIC database only once or
twice respectively.
Polymorphisms
Six of eighteen (50%) missense mutations and all the
three intronic variants (IVS 8–58 delT, IVS 7–34 C/T,
IVS 18 + 66G/A) are reported as polymorphisms in the
BIC database (Table 3). Of these, the most frequent, in
our study, are: E1038G (62%), S1613G (54%), P871L
(51%) and K1183R (49%).
Silent mutation
Three missense mutations (2201C/T, 2430T/C, 4427T/
C) resulted as neutral variant since the nucleotide
change did not influence the amino acids change and
the BRCA1 protein function (Table 3).
Clinical–pathological features of breast and ovarian
cancers
We obtained data on ER/PgR, c-erbB-2 immuno-
staining for all 14 BRCA1 mutation carriers affected
by BC of the present series. Nine (64%) were ER/PgR
negative, four (28%) were ER/PgR positive and one
(7%) was negative only for ER. Eight (57%) tumors
were c-erbB-2 positive (Table 4).
Both BRCA1 mutation carriers and non-carriers
presented mainly an invasive ductal carcinoma (IDC).
In addiction, the majority of BRCA1 positive patients
had an advanced grade breast cancer. BRCA1 negative
patients with OC presented mainly papillary cystoad-
enocarcinoma, while the majority of mutation carriers
had mucinous and papillary cystoadenocarcinomas
(Table 5).
Discussion
The present study on the molecular screening of the
BRCA1 gene in patients affected by breast and/or
ovarian cancers is the first conducted on a Sicilian
population. Up till now, the Italian Consortium of
Hereditary Breast and Ovarian Cancer has examined
272 Breast Cancer Res Treat (2007) 105:267–276
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1,758 families and has found that 14% of them prove to
be BRCA1 pathogenic mutation carriers [14]. Unfor-
tunately, these data have not included the incidence of
BRCA1 mutations in a Sicilian population. In this
study, the BRCA1 molecular screening conducted at
the ‘‘Regional Reference Center for the Character-
ization and Genetic Screening of Hereditary Tumors’’
at the University of Palermo showed a frequency of
BRCA1 mutations of 16%. In agreement with previous
Italian reports, in fact, [14, 26], 17 of the 106 unrelated
families included in this study proved to be carriers of
pathological mutations or UV mutations.
The identification of BRCA1 alterations strictly
depends on the adoption of specific criteria for the
selection of patients affected by breast and/or ovarian
cancer. Notwithstanding the fact that these criteria
have been defined by ASCO [23, 24], many reports
have shown a certain variability in their application
which often reflects the variability of the mutation
frequency [29, 30]. The results of this study show that
early onset of these tumors and family history are two
important selection criteria for the identification of
Sicilian patient carriers of the BRCA1 mutation. Ex-
cept for one index case of bilateral BC diagnosed at the
age of 43, in fact, all the families who were carriers of a
deleterious mutation had at least one member with
early-onset BC and/or OC. The present results are in
agreement with other studies [2, 10, 12, 31] which
indicate that the frequency of BRCA1 mutations de-
creases as the age of cancer onset increases.
Bearing in mind these extremely important selection
criteria, other groups have reported a mutation
frequency of 15% [31] or higher [32], in agreement
with our present study. Taking into account the overall
familial history, we found a major incidence of BRCA1
mutations (66%) in families with an HBOC profile. A
similar incidence was identified in a study involving 99
Italian index cases with breast and/or ovarian cancer
[33]. Moreover, as reported by Malander et al. [34], we
identified a higher frequency of BRCA1 mutations in
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Table 5. Pathological features of BC and OC patients occurring
in the study population according to the BRCA1 status.
Parameters BRCA1 – N(%) BRCA1+N(%)
Breast Cancer 84(86) 14(14)
Histopathologic type
IDC 67(80) 12(86)
IDC+LC 8(9.5) 1(7)
LC 8(9.5) 1(7)
Grades
G1 15(20) 0
G2 30(29) 5(36)
G3 20(26) 9(74)
Unknown 19(24) 0
Ovarian Cancer 11(71) 3(21)
Histopathologic type
Cap 6(60) 1(25)
Cap/m 3(30) 2(50)
AE 0 1(25)
CCA 1(10) 0
Grades
G1 0 0
G2 2(20) 2(50)
G3 1(10) 2(50)
Unknown 7(70) 0
IDC: Invasive Ductal Carcinoma; LC: Lobular Carcinoma; CAp:
Cystoadecarcinoma papillary; CAp/m :Cystoadecarcinoma
mucinous and papillary; AE: Adenocarcinoma Endometroid;
CCA: Clear Cell (mesonephroid) Adenocarcinoma
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OC patients when both familial and personal history
were considered as selection criteria.
BRCA1 related cancers are linked to an aggressive
tumoral phenotype and to a higher risk of development
of the same type of neoplasia in relatives, often at an
earlier age than that of the proband [31]. In this study,
in fact, after the analysis of I and II degree familiarity,
the relatives of 7/12 families carrying BRCA1 muta-
tions showed an earlier onset age (data not shown).
Two of seven (28%) male BC patients included in
this study were BRCA1 mutation carriers. In western
countries the frequency rate ranges from 0 to 4%
depending on the ethnic group [35–39]. Obviously,
more additional cases should be studied in order to
validate the frequency of the mutations identified in a
male Sicilian population.
BRCA1-associated carcinomas have been reported
to have typical characteristics in that they are more
frequently of the ductal invasive type, present a poorly
differentiated (G3) tumor, and are ER/PgR negative
and c-erbB-2 positive [3, 29, 40–42]. In accordance with
these data, all of these characteristics were also sig-
nificantly more frequent in our own series.
In this BRCA1 genetic screening two different
French mutations [43, 44], R1443X and 916delTT, were
identified in one male and in two woman respectively.
In particular, the R1443X is a French mutation re-
ported for the first time in 1997 in northern France and
subsequently listed 100 times in the BIC but only three
times in Italy. In addition, in a study conducted on a
French-Canadian population, the founder couple with
the highest probability of having introduced the muta-
tion into the Quebec population was identified [43].
The identification of BRCA1 mutations typical of a
French population in Sicilian patients can be explained
by the widespread allelic heterogeneity arising from the
several different dominations that Sicily has undergone
throughout the centuries.
In Italy, founder mutations have been identified in
restricted geographical areas. The 5083del19 has been
described in patients of Calabrian origin [18] and the
1499insA, probably a new founder mutation, in pa-
tients of Tuscany [26]. In our study, we found the
5083del19 mutation in 4 patients and all four families
confirmed their Sicilian origin. Since this pathological
mutation has been found by other research groups
conducting BRCA1 molecular screening in patients
originating from Central and Southern Italy [12, 18, 21,
29], we suggest that this mutation might well originate
from the South of Italy. Only a haplotype analysis will
make it possible to understand if all these families
originating from Southern Italy have a common
ancestor.
To our knowledge the 4843delC pathological
mutation [45] has never before been described and
reported in the BIC Database. This might well be a
Sicilian founder mutation, since it was identified in two
families who, although not related, came from the
same small geographical area of the south west of Pa-
lermo, in the Italian region of Sicily. Moreover, the
sequencing analysis conducted on the family members
has shown that this is a high penetrance mutation. Fi-
nally, in both index cases the same sequence variants
(seven SNPs) have been identified. Haplotype analysis
will subsequently be performed in order to see whether
these mutation carriers are likely to originate from a
common ancestor in the Sicilian population. Further
extension of this analysis to other families in the same
geographical area will be able to confirm the link be-
tween the high penetrance of the mutation and the
familial predisposition to breast and ovarian cancer.
Founder mutation identification, therefore, in popula-
tion-based studies with homogeneous ethnic back-
ground, would make it possible to use genetic testing in
routine clinical practice for the rapid recognition of
high-risk families in specific populations and could
have an impact on public health.
The assessment of a clinical significance to a specific
sequence variant require the following information: the
type and site of the mutation, the presence of the same
mutation in a control group, the co-segregation of the
variant and disease within families, the co-occurrence
with a deleterious mutation, the type of amino acid
change, the conservation of the amino acid across
species and the biochemical function [20]. For exam-
ple, the I68K variant, detected also in this study, was
studied by Morris et al. to predict pathogenicity and
disease-association by biochemical/functional experi-
ments [46]. They found that this substitution is located
inside the Ring finger domain of the BRCA1 protein
and brings about a folding alteration of the domain due
to its E2-ligase binding. In addition, it has been dem-
onstrated that the V740L and the A521T mutations,
reported respectively once and twice in this study, are
located in a strongly conservative site and are linked to
BRCA1-associated cancer [47, 48]. In this study, we
found sequence variants of unknown biological signif-
icance in the BIC database but potentially pathoge-
netic. Obviously this affirmation, based on the
mutational analysis of a population of 50 control cases
and on the conclusion that the majority of UV carriers
developing BC at an early age have no family history of
such tumors, should be confirmed by additional
experiments. Two unclassified missense substitutions
(Y179C and N550H) and a neutral/LCS missense
substitution (F486L) have been identified in cis in a
274 Breast Cancer Res Treat (2007) 105:267–276
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single patient [49]. Tavtigian et al. has shown that these
three variants are always found together, perhaps as a
rare haplotype and are quite probably associated with
the disease [50]. In other studies, on the contrary, these
alterations have been found in trans with pathological
mutations, indicating that each single variant does not
represent a higher disease risk [20]. Based on our own
experience, it might well be that the presence of both
the substitutions in cis have a higher effect in the
structural alteration of the protein and in the devel-
opment of BRCA1-related tumors [49, 50]. More
extensive information regarding cancer predisposition
would be of critical importance to genetic counselors,
since such UV mutations lead to informative genetic
testing results.
In conclusion, the present study is the first BRCA1
disease-associated mutation analysis in Southern Italian
families. We found a percentage of BRCA1 mutations
(16%) among the Southern Italian population similar to
those reported in other countries. In this consecutive
series of Sicilian patients affected by breast and/or
ovarian cancers, the early age of onset of such tumors
and the association with the HBOC familial profile
could be two valid screening factors for the identifica-
tion of BRCA1 mutation carrier. We also identified a
pathological mutation (4843delC) as a possible Sicilian
founder mutation. Further analysis will be conducted in
order to confirm the link between the high penetrance
of the mutation and the familial predisposition to breast
and ovarian cancer with the aim of using genetic testing
in routine clinical practice for the rapid recognition of
high-risk families in specific populations.
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